The next generation biopharmaceuticals

Affibody AB enter into an Option Agreement regarding cancer-targeting molecules

2016-04-13

Solna, Sweden, April 13, 2016 – Affibody AB (“Affibody”) today announced that the company has signed a Feasibility Study and Product Option Agreement with an unnamed partner.

The agreement relates to the therapeutic use of Affibody’s proprietary cancer targeting Affibody® molecules.

Further details of the agreement have not been disclosed.  

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing. Affibody has ongoing commercial relationships with several companies including Abclon, Biotest, Daewoong, Daiichi Sankyo, GE, Medimmune, Nordic Nanovector, and Swedish Orphan Biovitrum.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Year-end report (February 24, 2017)